Roche pursues companion diagnostic for schizophrenia drug; U-Systems' automated breast ultrasound deemed 'approvable';

 @FierceMedDev: Medtronic's latest study attempts to convince you that CRT-Ds are a bargain. More | Follow @FierceMedDev

> Roche is developing a companion diagnostic for its schizophrenia drug, the company's head of neuroscience told Bloomberg. Story

> U-Systems has received a PMA approvable letter from the FDA regarding the company's new automated breast ultrasound system. Release

> Investors are eyeing companies such as OPKO Health, Forbes asserts, which is developing a blood-based diagnostic test for Alzheimer's disease and plans to launch a diagnostic screening system for prostate cancer in Europe later this year. Story

> iRhythm's Zio Patch, a small adhesive bandage that can continuously monitor a patient's heart rhythm for about two weeks, has shown promise in a clinical study conducted by Scripps Health physicians and others. Release

> Curetis AG, a molecular diagnostics company based in Germany, gained a CE mark for its Unyvero instruments and P50 pneumonia diagnostics cartridge. Both products are rolling out commercially. Release

> SQI Diagnostics in Toronto has closed a private placement funding round designed to support further development of its IVD autoimmune test panels. Release

> Angel Biotechnology Holdings has acquired the assets of a biomaterial and collagen manufacturing business. Release

Pharma News

 @FiercePharma: Merck Serono workers threaten to strike in opposition to Geneva HQ closure. Already, protestors have hit the streets. | Follow @FiercePharma

> Eisai broadens marketing deal for Arena's weight-loss drug. Story

> Sales-needy Takeda springs for emerging markets growth. Article

> Servier, founder face trial on Mediator charges. News

Biotech News

 @FierceBiotech: FDA panel gave Gilead's key HIV drug Quad the OK on Friday. More | Follow @FierceBiotech

 @RyanMFierce: Category: Things CROs are good at. Wrong answer: Patient recruitment for clinical trials. Article | Follow @RyanMFierce

 @JohnCFierce: Come back from vacation to find lorcaserin looking pretty good for an approval. But how much could Arena really make from it? | Follow @JohnCFierce

> OncoMed offers $115M IPO bet on cancer stem cell work. Article

> Cancer drug developers angling for center stage at ASCO. More

> Big Pharma's high-risk pursuit of CNS gold faces major market doubts. Story

Biotech IT News

> BioClinica chief touts Microsoft ties in Q1 report. News

> Boehringer, pharmas turn to social gaming for online outreach. Article

> Roche unit allies with genomics software group SoftGenetics. More

And Finally... Medical device inventors and entrepreneurs Dean Kamen and Thomas Fogarty will take part in a panel discussion focused on the future of the industry on May 23 at the Medical Design and Manufacturing East conference in Philadelphia, at the Pennsylvania Convention Center. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.